Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
ResMed Inc.
RMD
NYSE·Healthcare·Medical - Devices·Mkt cap $29.2B
$208.77
▲ +3.81%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$180.27 - $293.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced proprietary medical technologies
- Global distribution network across 140 countries
- Comprehensive cloud-based patient management platform
- Strong intellectual property portfolio
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Rising global sleep apnea diagnosis rates
Value
Fairly valued vs Medical Devices peers
Momentum
Weak
-10.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
1.19% yield
Smart-money signal
Who's buying RMD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 21, 2026
APR 30, 2026
Reported EPS of $2.86 vs $2.79 consensus (+2.5% surprise). Revenue of $1.4B vs $1.4B expected (+0.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+2.5%
Next: Apr 21, 2026
Revenue trend · last 8Q
—
—
+10%
+8%
+10%
+9%
+11%
+11%
Q4 24
Q1 24
Q2 24
Q3 25
Q4 25
Q1 25
Q2 25
Q3 26
$1.2B
$1.2B
$1.3B
$1.3B
$1.3B
$1.3B
$1.4B
$1.4B
Margins · last 8Q
Gross
62.2%
Operating
34.9%
Profit
27.9%
Wall Street consensus
7 analysts · 57% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
57%
Hold
43%
Sell
0%
Median Price Target
$255.00
▲ +22.1% vs $208.77
Latest: Goldman Sachs · Jul 1, 2026
3 analysts covering